awmsg logo



fentanyl (PecFent®)


Reference No. 756

Publication date:
07/09/2011


Appraisal information

fentanyl (PecFent®) nasal spray


Company: Archimedes Pharma UK Ltd
BNF category: Central nervous system
NMG meeting date: 09/06/2011
AWMSG meeting date: 13/07/2011
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0911
Ministerial ratification: 01/09/2011

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fentanyl (PecFent®) is recommended as an option for use within NHS Wales for the management of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain. Fentanyl (PecFent®) should be initiated by, and remain under the supervision of, a specialist physician experienced in the management of opioid therapy in cancer patients. AWMSG is of the opinion that fentanyl (PecFent®) may be suitable for shared care within NHS Wales for the above indication.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download